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Executive Summary 
 
This quantitative, non-experimental, retrospective chart review investigated the 
possible presence of clinician driven disparities in the care of Black/African American 
patients with diabetes at an urban clinic.  The study was a response to the Institute of 
Medicine’s call to address patient, system, and clinician issues that negatively impact 
management of patients with chronic diseases including diabetes.  The goal is to 
improve patient outcomes using system wide care guidelines to increase success at 
meeting the nationally accepted Diabetes 5 (D5) measures. 
During a twelve month period, clinician response to elevated low density 
lipoproteins (LDLs) was assessed while considering patient preferences, side effects of 
medications, economic issues, and patient adherence.  Patients were divided into 
groups with either government or private insurance and by race/ethnicity.  The sample 
consisted of 75 individuals, 41 Caucasian, 19 African Americans, and 15 Eastern 
Africans.   
The study used an unvalidated diabetes chart assessment tool developed by the 
researcher.  Information regarding other LDL related comorbidities were tracked 
including body mass index and hypertension.  The study was guided by the social 
justice theory and Wagner’s Chronic Care Model. 
Findings of the study did not support clinician driven disparities. However, it 
was evident there is room for improvement in LDL management of patients in the 
study regardless of race or socioeconomic status.   
The research makes several recommendations for systems changes to improve 
outcomes of diabetes management of all patients at the clinic. 
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Chapter 1 
Background and Significance of the Study 
The Centers for Disease Control (CDC, 2010) estimated 24 million people 
in the United States have diabetes.  Of these, approximately 18 million people 
have been diagnosed with diabetes; 6 million have diabetes but are currently 
undiagnosed. Nearly all undiagnosed individuals have Type 2 diabetes.  Type 1 
diabetes accounts for 5-10% of the disease and occurs mainly in children and 
adolescents 18 years and younger. Type 2 diabetes usually occurs in adults, most 
commonly diagnosed after 60 years of age, and accounts for 90% to 95% of all 
diagnosed cases. 
 In 2007, uncontrolled diabetes is recorded on death certificates as the 7th 
leading cause of death.  However, it is estimated the number of patients who die of 
diabetes is greatly underreported (CDC, 2007).  According to the CDC’s Healthy 
People 2010 progress review (2005), deaths from diabetes are two times higher in the 
African American population than they are in Caucasians.   
All of these numbers are expected to rise as it is estimated the incidence of 
diabetes in the United States is increasing to near epidemic proportions with 
approximately 1.6 million new cases diagnosed annually in all ethnic groups.  Healthy 
People 2010, a national initiative,  notes that improved data collection and surveillance 
systems are, to some degree, factors that are contributing to the increased reported 
numbers in patients with diabetes. 
 Information available on Caucasians adults indicates that 14.9 million (9.8% of 
the population) have diagnosed or undiagnosed diabetes.  In 2007, sufficient data were 
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not available to derive prevalence estimates of both diagnosed and undiagnosed 
diabetes for all minority populations. However, available information regarding non-
Hispanic Blacks in this age group indicated that 3.7 million or 14.7% had diagnosed 
and undiagnosed diabetes (Magwood, Zapka, & Jenkins, 2008).  Updated information 
in a CDC press release dated June 24, 2008 reported “the rate of diagnosed diabetes 
was highest among Native Americans and Alaska Natives (16.5 percent). . . . followed 
by blacks [sic] (11.8 percent) and Hispanics (10.4 percent), [including Puerto Ricans, 
Mexican Americans, and Cubans].  By comparison, the rate for Asian Americans was 
7.5 percent with whites [sic] at 6.6 percent “(CDC, 2008, p. 1).   
 Diabetes can lead to unfortunate and expensive complications including 
cardiovascular disease, strokes, blindness, end stage renal disease, neuropathy, erectile 
dysfunction, and non-traumatic lower limb amputations.  Ethnic minorities, including 
African Americans, are disproportionally affected by diabetes and consequently suffer 
disproportionately from long term complications of the disease.   
 Not surprisingly, Barnes et al. (2004) note the cost of health care is four times 
greater for patients with diabetes than for individuals without diabetes with $174 
billion spent for both direct ($116 billion) and indirect ($58 billion) health care costs.  
Direct costs include illness requiring medical care, procedures, medications, insulin, x-
rays, and surgery. Examples of indirect costs include unnecessary illness, expense, 
work loss, premature mortality, and disability.   
 It has long been recognized that ethnic/racial minorities in the United States 
receive suboptimal health care.  In 1998, Congress commissioned the Institute of 
Medicine (IOM) to examine issues of disparity and implications for patient care, 
research, and education. In 1999, the IOM published its Unequal Treatment Report 
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which verified the presence of disparities in health care citing patient factors, system 
factors, and clinician factors as contributing to the inequity (IOM, 2003).  In the report 
Crossing the Quality Chasm: 2001, the IOM noted sizable gaps in health care quality 
with diabetes as one of 20 priority areas for improvement.  The report called for 
“substantial improvements in six major aims–that health care be safe, effective, 
patient-centered, timely, efficient, and equitable” (p. 11).  Healthy People 2010 builds 
on health care information from the past twenty years and contains 467 objectives for 
improved health care (including care of patients with diabetes) for the years 2000-
2010.  Healthy People 2010 delineates two overarching goals—to increase quality and 
years of healthy life and to eliminate health care disparities (HHS, 2005). 
The United States is making dramatic improvements in overall health and life 
expectancy of its citizens including those with diabetes.  For example, the adjusted rate 
of diabetes related deaths in all patients has dropped from  7.6 per 1000 in 2003 to 
3.0% per 100,000 in 2009 (CDC, 2009).   Despite this improvement, national data 
continue to indicate that minority Americans have poorer health outcomes from 
preventable and treatable diseases (including diabetes) when compared to Caucasians. 
According to Bach et al., when treatment disparities are eliminated, disparities in 
health outcomes are substantially attenuated or absent (2002). 
On a local level, the Minnesota Department of Human Services and Minnesota 
Community Measures (MNCM) have adopted the nine nationally accepted health care 
measures of care, one of which includes optimal diabetes care.  For the last two years, 
MNCM has compiled a report comparing the performance of clinics and medical 
groups within the state on these measures.  The patients are divided into two groups: 
residents of Minnesota whose health care is covered under government insurance, the 
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Minnesota Health Care Programs (MHCP), and those who have private, purchased 
(other) health care insurance.  A disproportionately higher number of individuals from 
ethnic/racial minorities in Minnesota are from a population with a lower 
socioeconomic status (SES) and are insured through government plans (Minnesota 
Community Measurement, 2009, Executive Summary).  Statistics regarding type of 
insurance are important because the prevalence of obesity (a risk factor for diabetes) 
and diabetes are inversely related to socioeconomic status (Betancourt & Maina, 
2004); type of insurance is often used as a measure of SES.  In addition, these authors 
found disparities exist even in insured minorities. This is in agreement with the IOM 
report (2003) indicating racial and ethnic minorities receive lower quality of health 
care even when medical insurance and income levels are the same.  
The 2008 Health Care Disparities Report for Minnesota Health Care Program 
determined that, using the IOM’s quality measures, “. . . performance in achieving 
high quality care was significantly lower at both the statewide and medical group 
levels for MHCP compared with Other Purchasers. . . .(although) gaps in performance 
between MHCP and Other Purchasers have narrowed for all measures. . . . (including) 
optimal diabetes care” (mnhealthscores.org, 2009, p. 5).   The D5 is a nationally 
accepted measure of adequate diabetes care and includes reaching the following five 
measures: 1) hemoglobin A1C below 7%; 2) blood pressure below 130/80; 3) low 
density lipoprotein below 100; 4) use of one aspirin daily and 5) nonsmoking status.  
Statewide, 7.8% of diabetic patients with MHCP have reached a D5; 13.4% of patients 
with private (Other) insurance have reached a D5 (Minnesota Community 
Measurements, 2009).    
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Quality measures at the large health care system where this study took place 
have improved in several MNCM quality measures and have shown some, but not 
optimal, improvement in the area of diabetes care.  According to MNCM, this care 
system ranks sixth out of the eight major health care systems in the Twin Cities area in 
percentage of patients who have achieved a D5 score (Minnesota Health Scores, 
2008).  The system’s goal in 2009 for D5 scores (with A1C of below7.0%) was 20%.  
The percentage of D5s across the system was 14% in 2008 and 19% as of March, 
2009.  The average D5 among the 18 primary care clinics was 22.8%.  The urban 
clinic where the study took place has a high percentage of individuals with 
government insurance and consistently has the lowest percent of patients with a D5 
reaching only 13% at the end of March 2009 (health care system statistics, 2009). 
The researcher met with a leading endocrinologist at the health care system to 
discuss parameters of the study.  The number of patients with elevated hemoglobin 
A1C levels and elevated low density lipoprotein, both of which are outcome measures 
of the D5, varied from month to month at the clinic where the study took place.  
Treatment of elevated blood glucose involves considerably more options than those to 
treat elevated lipoproteins; for these reasons this study tracked clinician response to 
LDL values when investigating the possibility of clinician driven disparities. 
The clinic is located in an area where there is a large Eastern African 
population.  The endocrinologist suggested the researcher also separate patients from 
Eastern Africa from those patients who indicated race/ethnicity as Black/African 
American to look for any differences within the Eastern African population related to 
diabetes care.  
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 The researcher is a certified nurse practitioner and clinical practice director 
(CPD) at this large urban clinic.  As a CPD, one of the researcher’s responsibilities is 
to work toward improved patient care and outcomes, including those of patients with 
diabetes.  Optimal diabetes care measures at the clinic have consistently been the 
lowest when compared to all other primary care clinics within this health care system 
and suggest ethnic/racial disparities in care. For example, 34.5% of Caucasian and 
12% of Black/African Americans had LDLs under control throughout this study (see 
Appendix A, sample size, inclusion and exclusion criteria).  During meetings related to 
improving diabetes care outcome measures, clinicians at the clinic most often cite 
patient issues as an explanation of suboptimal outcome indicators.  This explanation 
coincides with the findings by Sequist, Ayanian, Marshall, Fitzmaurice, and Safran 
(2008) who noted that clinicians were more likely to perceive patient factors than 
clinician or systems factors as contributing to less than optimal patient care outcomes. 
 Improved diabetes care outcomes should lead to improved health of patients of 
the system and would decrease the number, and therefore, cost of care of individuals 
who experience long term complications of diabetes. The cost of patient care may 
decrease as, according to Stewart et al. (2000), common ground in clinician-patient 
interactions is associated with “. . . better (patient) recovery . . . . and (appropriately) 
fewer diagnostic tests and referrals” (p. 796).     
 In addition to improved patient outcomes, this health care system could benefit 
from financial incentives offered by third party payers.  These payers are providing 
substantial bonuses to health care systems who meet the benchmark goals of the D5 in 
the care of diabetes patients.  According to the director of health support for this health 
care system (personal communication, July 25, 2009),  one internal medicine site 
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within the system is currently participating in a pilot program with five payers, the 
majority of which provide $50 per patient per month to manage care of patients with 
diabetes who do not meet the D5 benchmarks. Two of these payers have provided the 
health care system with a grant to support this pilot project. According to information 
presented at the July 7, 2009 clinical practice directors and clinician managers 
meeting, “(This health care system) is at risk for more than $1 million in pay for 
performance withhold from our payers” In this statement, the presenter was referring 
to reimbursements from third party payers to health care systems that reach benchmark 
goals of patient care thereby.decreasing cost of care to enrollees in the managed care 
plan  
Research Question 
 Are there clinician driven disparities in the care of Black/African American patients 
with diabetes? 
 Hypothesis: 
 There are clinician driven disparities in the care of Black/African American 
patients with diabetes when compared to care of Caucasians. 
 There is a need for system change if the low density level of  
       Black/African American patients is out of control more often than those of Caucasians  
 and/or if there are differences in the number of actions clinicians take to address  
 elevated LDL levels in patients of different race/ethnicity.   
Challenges of the Study 
 This study found no clinician driven disparities.  Examining this issue was 
important since most clinicians agree health care disparities occur at the national or 
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state level and even within the community where the clinician practices but do not feel 
disparities occur with patients under his/her care (Sequist et al. 2008).   
Clinicians often report there is not enough time for optimal diabetes care and 
that they are being asked to provide more care with the same or fewer resources 
(Bodenheimer, Wagner, & Grumbach, 2002). When clinicians are under increased 
stress and time pressures there is a subconscious tendency to categorize or stereotype 
beliefs and expectations based on ethnicity in an effort to simplify and shortcut 
decision making (Betancourt & Maina, 2004).  
 This study depends on race/ethnicity as supplied by the patient when 
registering at the clinic for an initial appointment.  The clinic manager estimates 95% 
of patients register over the phone and are asked about their ethnicity using a standard 
race/ethnicity selection form.  The remainder of patients register at the front desk; on 
some occasions and for various reasons, staff find it necessary to make reasonable 
guesses regarding patient ethnic/racial background.  Information regarding preferred 
patient language and need for interpreter are also gathered.  While this is an imperfect 
process, the efforts of this health care system are more forward-thinking than the many 
institutions which have not yet begun to collect any information regarding 
race/ethnicity making it impossible to understand and track progress toward improved 
care and outcomes of minority populations (Betancourt & Maina, 2004).   
Project Objectives  
 The purpose of the study was to determine if clinician driven disparities exist 
in the care of Black/African American patients with diabetes at this large urban clinic. 
 Data collection was performed to determine if both Caucasian and Black/African 
American patients with diabetes received equal and appropriate care in management of 
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LDL levels.  The study tracked appropriate use of lifestyle coaching and the use of 
statins as outlined in the organization’s standards of care.  Patient preferences, 
economic challenges, and patient response to clinician recommendations were 
monitored since any of these issues may affect the clinician’s ability to move forward 
in interventions to improve care outcomes.  Analysis attempted to determine if levels 
of care differ related to race/ethnicity and/or type of insurance.   
Social Justice Theory 
The ultimate goal of this project is to improve the care of all patients with 
diabetes through equitable care, improved management of diabetes, avoidance of 
complications of diabetes, and premature deaths. It is expected improved care of 
ethnically/racially diverse patients will also have a positive impact on care of all 
patients with diabetes, including Caucasians. An understanding of clinician issues 
related to inequities in care is necessary before action can be taken to address the 
problem at clinic, system, community, and national levels.  Actions toward inequities 
in care are appropriately addressed through the lens of social justice. 
Social justice has six dimensions: health, personal security, reasoning, respect 
of others, attachment, and self-determination (Mathis, 2007).  It is the principle of 
moral rightness and equity as applied to individuals living together in communities 
and sees each individual as an equal part of who we are as a society.  In her 
presentation in 2008, Sister Amata Miller explained social justice attends to the needs 
of the individual, looks for answers to inequities and calls for a social response 
(action) to address a problem.  It demands fair and impartial treatment of others and 
conformity to moral rightness in attitude and action.   
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Social justice refers to institutions in society that aspire to fairness between two 
individuals (or between an individual and a group) and holds the government 
responsible for equitable distribution of the goods of society.  Social justice requires 
skills of “inspiring, working with, and organizing others to accomplish together a work 
of justice . . . . it aims at the good of the city, not at the good of one agent only 
“(Novak, 2000, p. 2).  Equality in health care means provision of care that does not 
differ in quality because of ethnicity or socioeconomic status and is included as a goal 
of and commitment to equity in health care outcomes in the 21st century (Crossing the 
Quality Chasm, 2001).  
In Unequal Treatment (2003), health care is determined to be a resource, a 
social good, tied to social justice and quality of life for individuals and groups.  In his 
work, Distrust, Social Justice, and Health Care (1999), McGary notes most 
individuals in the United States view health care as a “primary good” that every 
rational person is presumed to want.  The author refers to the writings of Dr. Rawlings, 
a leading political philosopher, on the subject of social justice. “Rawlings argues that 
the allocation of these goods is subject to the contraints of justice . . . . (and contends)  
. . . . that the least-advantaged members of society, as measured by their possession of 
the primary goods, should be the gauge by which we judge the justness of the basic 
structure of society” (p. 236).  McGary sees justice as a first virtue of social 
institutions which are responsible for establishment of rules of society.  Where 
injustice is seen, the state has a mandate to take action to eliminate or mitigate the 
inequality.  The author refers to the resulting general distrust by Blacks/African 
Americans of all public institutions (and particularly the health care system) based, in 
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part, on the gross injustices and breaches of trust by the medical community toward 
minorities and especially African Americans. 
 In her compelling book, Medical Apartheid, Washington (2006) writes of the 
long history of injustices, particularly medical experimentation, perpetrated upon 
minority individuals extending back to at least the eighteenth century as “more than a 
historical fact. Although less rife, it remains a contemporary reality, and an ever-
present possibility” (p.386).  Washington acknowledges that medical research 
involving minorities today is much safer and, in fact, necessary to address health care 
issues, particularly those that affect Blacks/African Americans in  greater numbers or 
level of severity. Washington encourages African Americans to welcome and 
participate in medical research while remaining wary of research abuses. She cautions 
that “Both the federal government and private corporations have devised large-scale 
research abuses that range from radiation experiments to biological-weapons 
development. This medical ill-usage has not strictly paralleled scientific knowledge: 
Rather, it has mirrored the larger American cultural beliefs as well as politics and 
economic trends “(p. 385). 
 McGary (1999) notes the perception of unfair treatment by the health care 
system does not mean the inequity actually is occurring.  However, McGary proports 
the health care system has a responsibility to acknowledge the history of this distrust 
and correct erroneous perceptions. This is good counsel for the government given this 
nation’s long history of laws and policies that condoned discrimination until the Civil 
Rights Acts of 1964 and 1968.  Policymakers have long known of disparities in health 
care and have established eliminating health care disparities as a priority. It is 
important for researchers in health care to explain the value of ethical research and 
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changes in health care that focus on the ethnically or racially diverse.  These special 
efforts, without being excessive, may reestablish confidence in these basic institutions 
of society.  
  Nursing codes of ethics “identify standards of practice, detail provision of 
particular services, and address fiduciary relationships that are essential hallmarks of 
any profession (Salladay, 2008).  These codes hold the nurse accountable as an 
individual who has a special relationship of trust, confidence, or responsibility to 
others.  As a guide for action based on social values and needs, the Code of Ethics for 
Nurses with Interpretive Statements (2008) assigns nurses the fundamental 
responsibility for promotion and restoration of health in care of patients and 
communities without regard of race or economic status.  Crigger (2008) notes nurses 
are committed to justice in health care and are called to be responsive to differences in 
health resources and resource distribution.  Nurses need to raise the moral sensibility 
of unfairness and are encouraged to engage in social justice at local, national, and 
international levels. The author states: “Nursing is potentially a very powerful 
international discipline, a from below agency, that can impact on social, economic and 
political climate of the world” (p. 21). 
 Nurse practitioners (NPs), in particular, have a mandate and are uniquely 
positioned to address issues of social justice while working to improve the health of 
others.  In their article, Examining the Potential of Nurse Practitioners from a Critical 
Social Justice Perspective, Browne and Tarlier (2008) note “. . . we have come to 
recognize the ‘value added’ component of NP practice – namely, the social justice 
aspects of the role in the context of illness treatment, health promotion and prevention 
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services “(p. 89).  Nurse practitioners must advocate for changes that are at the root of 
practices that perpetuate inequities.  
 This system change project is based on principles of social justice and is the 
first step in determining the need for action aimed toward the reduction of health care 
disparities of patients within the clinic and throughout the health care system. 
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Chapter 2 
Theoretical Framework 
Wagner’s Chronic Care Model is the theory supporting this system change  
project.  Dr. Wagner proposes a reorganization and redesign of a different type of care 
system more tailored to the needs of patients with chronic illnesses. Wagner includes 
six interrelated components of care that guide improved management of patients with 
chronic disease.  These six components are self-management support, clinical 
information systems, delivery systems redesign, decision support, health care 
organization, and community resources. Decision support includes the use of evidence 
based practice clinical guidelines into patient care of individuals with chronic diseases 
(Bodenheimer, Wagner, & Grumbach, 2002a).   Wagner’s model strives for  improved 
health care outcomes as the result of  productive interactions between an informed, 
activated patient and a prepared, proactive practice team.  
The health care system where this study took place regularly disseminates 
information regarding updated practice guidelines for the care of patients with 
diabetes.  A diabetes registry is updated and distributed monthly to all clinicians 
involved in primary care of patients with diabetes.  The registry includes information 
regarding current measures of each patient’s progress toward a D5.  During the time of 
this study, each clinician/nurse team worked together to manage the registries although 
with varied success.  In his Chronic Care Model, Wagner recommends that one 
individual at each clinic be assigned the responsibility of working the registries. 
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Literature Review 
Background 
As stated earlier, when the IOM published its Unequal Treatment Report  
(verifying disparities in health care of minorities), patient factors, system factors, and 
clinician factors were identified as contributing to the disparities (2003).  
  Patient issues. 
Healthy People 2010 (2005) cites many patient issues that may contribute to  
health care disparities in patients with diabetes.  These include but are not limited to 
“Westernization” of diet (increased fats and processed foods), demographic changes, 
decreased physical activity, genetics, socioeconomic status, level of patient 
knowledge, and cultural and community traditions.  Another proposed patient factor is 
the belief that African Americans have a stronger sense of the present and a fatalistic 
view of their diabetes believing the disease and associated complications are inevitable 
and unpreventable (Barnes et al. 2004).  Dagago, Funnell, and Davidson (2006) found 
that, as a group, African American individuals are usually aware of the increased 
incidence of diabetes in the African American population but have a lower level of 
understanding of the complications of diabetes.   
 Adverse social determinants also contribute to patient factors.  These include a 
lower level of education, inadequate or unsafe housing, racism, and living in close 
proximity to environmental hazards (Betancourt & Maina, 2004).  Dovidio et al. 
(2008) noted unequal distribution of medical services and the associated poor access to 
health care as two system factors that disproportionately and negatively affect the 
health care of Black/African American patients.  Although there is a belief that 
ethnic/racial minorities show poor adherence to treatment regimens, Egede and 
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Dagago (2005) note there is no evidence for ethnic nonadherence to treatment plans 
with the exception of self blood glucose monitoring (SBGM).  However, almost all 
patients with diabetes monitor their blood glucose less frequently than recommended 
with 18% of African Americans and 30% of Caucasian patients testing at minimal 
recommendations. These authors recommend clinicians not assume lack of adherence 
to a treatment plan until the patient reports that this is actually the case.   
Another patient issue, some aspects of which are intertwined with systems  
issues, is lack of health care insurance in the minority population.  Betancourt and 
Maina (2004) reported a disproportionate number of minorities are uninsured:  20% of 
African Americans are uninsured as compared to only 11% of Caucasian patients.  In 
addition, diabetes care and outcomes can be affected by insurance issues when 
clinicians make incorrect assumptions regarding the person’s insurance status and 
likelihood of adherence to a treatment plan.  Kirk et al (2005) note clinicians may 
make incorrect assumptions regarding minority patients’ insurance coverage which 
can adversely affect other care decisions including additional testing and referrals.  
Lurie et al. (2005) came to that same conclusion when researching disparities in 
referrals among cardiologist noting that “. . . referral decisions were often based on 
incorrect assumptions about patient insurance status. In other words, the physician 
often assumed that the patient was uninsured when this was, in fact, not the case” (p. 
1269).   
 Systems issues. 
 System issues refer to the manner in which health care is structured at a systems level 
and may affect patient ability or willingness to seek or continue with health care.   Historic 
and contemporary inequalities have led to a persistent wariness between the medical 
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community and Black African/ American patients which can affect the climate of health care 
interactions and health care outcomes. Betancourt and Maina (2004) reported 65% of African 
American patients are afraid of being treated unfairly at future health care visits while only 
22% of Caucasians individuals have that same concern.  This distrust between the Black/ 
African American population and clinician-researchers continues to contribute to the 
underrepresentation of minorities in contemporary health care research.  According to Clark 
(2009), “. . . although African Americans make up only 13% of the United States population, 
they account for almost half of the estimated number of HIV/AIDS diagnoses made during 
2006“ (p.123).  However, non-Hispanic Blacks and Hispanic patients were less likely to 
participate in trials than Caucasians and, therefore, less likely to receive experimental 
medications. These authors note the work of J. Merz who wrote that underrepresentation in 
clinical trials “leads to results that do not account for a host of factors. . . that could have a 
huge impact on how well new drugs do in the real world” (p. 1). 
  As noted by the IOM in Shaping the Future for Health (2001), other system problems 
include language barriers, fragmented health care systems (where minorities are enrolled in 
government programs, often with greater limitations on health care expenditures), and 
incentives to clinicians to limit services. Even when minorities and Caucasians have the same 
type of insurance, the location of and/or lack of access to care for these potentially expensive 
patients can be a barrier.   
 Clinician issues. 
 The third factor noted by the IOM as contributing to health care disparities is clinician 
issues. According to Larme and Pugh (1998), medicine is driven by symptoms. These authors 
address the appeal of treating acute illnesses while chronic care (with few or no immediate 
symptoms) requires efforts toward preventing complications that may not occur for many 
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years. It is easier and more gratifying to treat and provide relief to those who are experiencing 
symptoms at the time of the visit.  The authors contend the emphasis of medical education and 
continued medication education is more often focused on acute problems and illnesses and is 
less effective in imparting information related toward improved chronic disease management.  
In addition, the authors note the treatment of diabetes is labor intensive and time consuming.  
Clinicians are aware that SBGM causes pain to patients instead of immediate alleviation of 
symptoms.  Clinicians are slow to adopt standards of care and have a negative opinion of the 
flow sheets used to track care measures.  The authors note that “Primary care providers have 
the most negative attitudes about diabetes, yet they provide 80% of all office visits for 
diabetes mellitus “(p. 1391). 
 Bodenheimer, Wagner, and Grumbach (2002a) refer to the “tyranny of the urgent”. 
“Frequently, the acute symptoms and concerns of the patient crowd out the less urgent need to 
bring chronic illness under optimal management. . . . patients are not adequately taught to care 
for their own illnesses. . . . Too often, caring for chronic illness features an uninformed 
passive patient interacting with an unprepared practice team, resulting in frustrating, 
inadequate encounters” (pp. 1-2).  These authors recommend creation of practice teams that 
integrate evidence-based clinicial practice guidelines into care of patients with chronic 
illnesses.  
  Clinician inertia, the recognition of a problem but failure to act, has been 
attributed to an overestimation of care provided, the use of “soft” reasons to delay 
increased use of medications, and/or a lack of focus on therapeutic goals (Phillips et 
al., 2001).  For example, a clinician fails to advance therapy in a nonadherent, 
morbidly obese patient who has had time and expressed intent to improve glycemic 
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control and eating habits but whose diabetes remains uncontrolled and who has not 
gone forward with changes in eating habits.   
In addition, clinicians feel there is not enough time for diabetes care. Bodenheimer, 
Wagner, and Grumbach (2002b) noted clinicians often had only ten minutes of face-to-face 
time with the patient, five of which was spent on diabetes management.  Under these 
circumstances, although 65% of the patients had an average HgbA1C of 8.9%, therapy was 
intensified only 15% of the time.  Interestingly, there was no difference in quality of care 
between high and low volume clinicians. 
 In 2002b, these same authors describe the “hamster syndrome” in health care, i.e. the 
push to work harder with the same or, in some cases, fewer resources.  This syndrome leads to 
use of the conditioning phenomenon which involves assigning individuals to a group based on 
race, gender, or age and then applying group characteristics to individuals.  This conditioning 
phenomenon is used by all human beings, subconsciously and automatically, to simplify 
decision making and lessen cognitive effort.  Individuals are more likely to resort to this type 
of behavior when stressed as is often the case during a rushed health care visit. Some 
clinicians, however, have an overly positive view of the quality of care provided even under 
the above noted circumstances (Bodenheimer, Wagner, & Grumbach, 2002b).  In addition, 
many patient behaviors are related to less apparent socioeconomic factors (e.g. poverty) and 
not race, ethnicity, or cultural traditions (Betancourt & Maina, 2004). 
 The “Not Me” Phenomenon is the belief that racial disparities occur in health care but 
not in the individual clinician’s practice. “. . . Whereas the majority of primary-care clinicians 
support the collection of patient race and ethnicity data, only a minority report the presence of 
racial disparities in diabetes care among patients they personally treat" (Sequist et al. 2008, p. 
683).  These authors report that 88% of primary care providers nationally agree that disparities 
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occur but only 40% believe differences in care of minority patients would be noted in the 
clinician’s own patients/clinic.  A meta-analysis of 35 studies compiled by Kirk et al. (2005) 
cited data indicating “The major ethnic differences (in patients with diabetes) reported were 
lower rates of eye examination, influenza vaccination, and lipoprotein testing among 
Hispanics and African Americans than among non-Hispanic whites” (p. 349). 
Definition of Terms 
 Health care disparities. 
Braveman (2006) defines health disparities as “a difference in which 
disadvantaged social groups---such as the poor, racial/ethnic minorities, women, or 
other groups who have persistently experienced social disadvantage or discrimination-
---systematically experience worse health or greater health risks than more advantaged 
social groups” (p. 167). 
Low density lipoproteins. 
Cholesterol is a fat-like substance containing both lipids and proteins.  
Cholesterol travels in the blood and is present in cell membranes.  The three major 
classifications of lipoproteins measured in fasting serum are high density lipoproteins 
(HDL), low density lipoproteins (LDL), and very low density lipoproteins (VLDL).  
Sixty to seventy percent of cholesterol is made up of LDL which are the major 
atherogenic lipoproteins and the primary target of cholesterol-lowering therapies.  
Statins (or HMG-CoA reductase inhibitors) are a class of drug used to lower 
cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which plays a 
central role in the production of cholesterol in the liver.  Although LDL continues to 
receive primary attention, growing evidence indicates that VLDL and HDL also play 
an important role in atherogenesis.  Elevated HDL levels are inversely related to risk 
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of coronary heart disease.  Low HDL levels often reflect the presence of atherogenic 
factors.  VLDLs are precursors of LDL; some forms of VLDL appear to promote 
atherogenesis, similar to LDLs. 
 According to the National Institutes of Health’s ATP Panel III Final Report 
(2001), “Persons with type 2 diabetes have a 10-year risk for major coronary events 
(myocardial infarction and CHD [coronary heart disease] that approximates the risk in 
CHD patients without diabetes. . . . Thus type 2 diabetes constitutes a CHD risk 
equivalent” (p. II-53, National Institutes of Health, 2001.)  In patients with diabetes, 
aggressive cholesterol-lowering therapy still leaves absolute CHD rates far above 
those in low-risk populations (p. II-4.)  For this reason, treatment of LDLs in patients 
with type 2 diabetes should follow recommendations for persons with established 
CHD.  According to the Institute for Clinical Systems Improvement (ICSI, 2008), 
“The goal (for patients with diabetes) with CAD [coronary artery disease] is less than 
70 mg/dL. . . . even [in those patients] with a baseline LDL of  less than 100 mg/dL” 
(p. 26).  The NIH advises: 
Persons with LDL cholesterol ≥ 130 mg/dL generally require a statin drug to 
achieve LDL cholesterol < 100.  Therefore, a statin should be initiated 
simultanteously with TLC [therapeutic lifestyle changes] and maximal control 
of other risk factors. . . .[those] with LDL cholesterol ≥ 130 mg/dL generally 
will require an LDL-lowering drug to achieve LDL cholesterol < 100 mg/dL.  
(2001, p. IV-2).  
 This report maintains a goal of LDL under 100 in individuals with diabetes but 
 acknowledges there are differing recommendations regarding treatment of LDL in 
individuals whose level is between 100-129 mg/dL.  Some authorities recommend 
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initiation of statins if TLC do not bring the LDL level to < 100; others recommend use 
of drugs that modify other lipoprotein factors (High [HDL] and very low density 
lipoproteins [VDLD], and triglycerides) e.g. nicotinic acid and fibrates.  Still other 
sources allow the clinician to use clinical judgement in the decision to withhold drug 
treatment in these individuals (NIH, 2001.)  The care system where this study took 
place, as well as MNCM holds to an LDL of < 100 in individuals with diabetes; an 
LDL at this level remains the desired outcome measure in determination of the D5.  
Individuals under 18 or over 75 and those treated for active cancer are not included in 
the health care system’s diabetes registry.  
The health care system where this study took place includes lipid testing as part 
of diabetes standing orders (see Table 1). 
         Table 1 
          Diabetes Standing Orders 
          Lipid testing 
If Lab Test Frequency 
LDL ≥ 100 Chol Fx/AST Within 6-12 weeks 
No Lipid Med Chol Fx Within 12 months 
Stable Lipid Med Chol Fx/AST Within 12 months 
 
  
Lipid Testing 
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Chapter 3 
Methodology 
 Study design. 
This study was a quantitative, non-experimental, retrospective chart review.  
The study used lab values and office visits of patients seen within an 18 month time 
frame between January 1, 2008 and June 30, 2009.  Within this 18 month window, the 
goal was to have at least twelve consecutive months of data on each patient, beginning 
with the most recent primary care appointment between January 1, 2009 and June 30, 
2009 and working back in time through the medical records. 
Study sample. 
The target population was patients ages 18-75 inclusive with permanent Last 
Word addresses in Minnesota or Wisconsin, who have been seen in primary care for 
an outpatient clinic visit at least three times in the last 12 months, carried an ICD-9-
CM diabetes mellitus (250.xx) code on their problem list, and whose primary care 
clinician and diabetes clinician practice within the internal medicine department at the 
clinic.  
Inclusion/Exclusion criteria. 
In order to be included in the study, the patient had to have been seen at least 
three times within an 18 month window beginning January 1, 2008 and ending June 
30, 2009.  This initial query yielded a list of 417 patients, 235 Caucasians and 182 
Black/African Americans.  The focus of this study was to investigate clinician 
response to individuals with LDLs out of control.  For this reason, 103 patients had 
LDL values that were under control during the entire time frame of the study and so 
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were excluded.  Of this sample, 34.5% were Caucasian and 12.1% were Black/African 
American.  (Appendix A). 
There was inadequate lab data on 57 Caucasians (24.3%) and 57 Black/African 
Americans (31.3%).  A total of 12 patients were eliminated due to an inadequate 
number of office visits.   
This study investigated possible differences in care between African 
Americans and individuals who came to the United States from Eastern Africa.  In 
order to make as accurate a determination as possible, a review of the medical record 
was completed on all individuals who identified themselves as Black/African 
American.  Individuals whose demographic information indicated the need for an 
interpreter of a language spoken in Eastern African (e.g. Somali) or whose country of 
origin was dictated in the medical record as being from an Eastern African country 
were accepted as Eastern African and included in the study (see Appendix B for 
Eastern African countries and languages).  There were 31 individuals who indicated 
their race/ethnicity as being Black/African American but whose medical record gave 
no information as to whether the patient was of African American or Eastern African 
descent and so were excluded.  Fifteen patients whose medical record indicated 
country of origin as one on the continent of Africa but not from Eastern Africa (as 
defined by the CDC) or who were from other parts of the world were excluded. 
This study used type of insurance as an indicator of socioeconomic status.  
Thirty six patients were self-pay or had both government and private insurance and 
were excluded from the study (see Appendix C for list of government and private 
insurances).  Because this study included individuals ages 18-75, it is likely some 
patients excluded from the study because they had both government and private 
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insurance were individuals 65 and over who had Medicare and a privately purchased 
supplemental insurance.  Individuals who were missing lab data or had not been seen 
three times during the time frame of the study (114) were excluded.   
  From the original query of 417 patients, 194 (82.6%) Caucasians and 148 
(81.3%) Black/African Americans were excluded.  The final sample of 75 patients 
included 41 Caucasians and 34 Black/African Americans.  The researcher was able to 
determine that 15 of the 34 Black/African American sample were of Eastern African 
descent.   
 Research tool. 
The diabetes chart audit tool (Appendix D) was used to monitor actions taken 
by clinicians during and between office visits related to LDL testing to determine the 
presence or absence of health care disparities.  Chart review included a manual search 
for demographic and insurance information, review of office visit dictations, lab order 
forms, lab letters, telephone calls, pharmacy records, and health care records from 
other health care facilities imported into the patient medical record.   
The tool monitored sequencing and recommendations of lifestyle coaching, 
starting, changing, increasing, or discontinuation of a statin, and clinician 
recommendation to schedule a follow up appointment and/or lab draw.  Information 
regarding the number of patients who expressed concern regarding the cost of 
medication and clinician response to this information was entered on the tool.  
Because untoward side effects of statins could influence clinician actions this 
information was also tracked.  
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 The tool indicated the percentage of clinicians taking action for those patients 
whose LDLs were out of control during the time periods of the study.  Information 
from the tool was used to define four groups of patients: 
1) Those whose LDL was under control and taking a statin. 
2) Those whose LDL was under control and not taking a statin. 
3) Those whose LDL was not under control and taking a statin. 
4) Those whose LDL was not under control and not taking a statin. 
Each of these groups were then divided by race/ethnicity.  Tests for differences  
in percentage of patients with appropriate actions taken by clinicians and differences 
in proportions based on race were reported.   
 Body mass index. 
Obesity is a risk factor for many chronic diseases including diabetes and 
hypercholesterolemia.  The body mass index (BMI) is used to define normal weight, 
overweight, and obesity. Although the level of risk associated with BMI varies slightly 
depending on race/ethnicity, a person is considered overweight if the BMI is above 
24.9 and obese if the BMI is 30 or above.   
 Lifestyle changes. 
 Lifestyle changes (modifications of habits or patterns) are often recommended 
as a first line therapy for patients whose LDL is out of control.  Patients may request a 
trial of diet and exercise changes before starting on a statin. These changes are a 
mainstay of LDL management and, depending on the degree of LDL elevation, may 
prevent the need for statins.   
Complementary and alternative medicines. 
The tool monitored patient preference for use of complementary and  
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alternative medicines (CAM) before being started on a statin.  Patient decision to try a 
CAM is tracked since this is a patient decision and does not reflect clinician failure to 
respond to an elevated LDL value.   
CAM is a term currently accepted by the National Institutes of Health to 
describe alternative treatments used in place of or in tandem with pharmaceuticals 
prescribed by Western medicine to promote health or treat illness.  Many patients see a 
combination of CAM and conventional medicine as the optimal approach to their 
health care particularly when neither approach is viewed in a hierarchal manner.   
In their 2007 qualitative study of 37 regular users of IM, McCaffrey, Pugh, and 
O’Connor noted more than one-third of Americans preferred to use CAM or 
integrative medicine approaches for their health care needs. The participants in their 
study emphasized the centrality of the patient-clinician relationship “. . .[in which 
physicians are viewed] as guides rather than commanders “(p. 1500).  In 2004, a report 
released by the National Center for Complementary and Alternative Medicine 
(NCCAM) and the National Center for Health Statistics (NCHS)  showed that 36% of 
American adults were using some form of CAM (Vogel et al., 2005, p. 186).  In his 
presentation on 11/18/2009, Sash listed plant stanol/sterols, omega-3 (found in oily 
fish), flax seed, soluble or viscous fiber, antioxidants, and flavonoids as CAMs that 
have been shown to reduce LDL levels.   
 Patient preference. 
 Information regarding patient preference was gathered in the chart review tool.  
Patient preference has a direct impact on options available to a clinician in 
management of LDLs.   
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 Goff, Mazor, Meterko, Dodd, and Sabin (2007) state an estimated 20-50% of 
patients do not take medications as prescribed noting participant beliefs and 
preferences about medication prescribing as contributing factors.  These beliefs and 
preferences “. . . encompassed 3 major areas: patient-doctor relationships, outside 
influences, and professional expertise. . . . [and included] participants’ concerns about 
the pharmaceutical industry’s influence on doctors’ prescribing practices and belief 
that there is a clear ‘best’ medication for most health problems "(p. 236). 
 In their work exploring the phenomenon of saying “no” to recommendations of 
healthcare providers, Michaels, McEwen, and McArthur (2008) compared patient and 
professional cultures and their differing approaches to starting medications.  These 
authors note that, for some individuals, health care is needed only when symptoms 
directly impact the everyday experience.  A patient symptom based approach to 
diabetes and LDL management is one of the clinical challenges in treatment of chronic 
disease.  Chronic disease management requires convincing the patient to control their 
illness become developing symptoms of the long term or fatal complications of poorly 
controlled diabetes or LDLs.   
  The IOM (2001) calls for patient care based on best scientific knowledge 
while allowing for patient control.  The Institute notes that in order to meet both of 
these IOM recommendations, evidence-based practice requires and relies upon 
evidence-based individual decision making which can only be learned by listening to 
the client’s health stories, values, and beliefs.   
 Entwistle, Carter, Crubb, and McCaffery acknowledge the value of patient 
autonomy but caution that “. . .many health care practices can affect autonomy by 
virtue of their effects not only on patients’ treatment preferences and choices, but also 
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on their self-identities, self-evaluations and capabilities for autonomy” (2010, p. 741).  
The authors agree patients should be offered options, allowed and enabled to make 
voluntary choices but note discussions related to autonomy rarely address 
implementation of choices and required lifestyle changes.  “Patients may feel 
abandoned rather than autonomous if their clinicians refuse to do more than inform 
them about options and insist they choose. . . .  clinician interactions should support 
the autonomy of patients. . . by helping (patients) form, maintain or re-establish self-
identifies that they are comfortable with, and to deal with emotions and social stigma 
(of disease)” (p. 742).   
Ethical Considerations 
It is necessary to verify clinician driven disparities before moving forward to 
address clinician driven disparities in provision of health care to those from lower 
socio-economic backgrounds and/or of Black/African American ethnicity.  If clinician 
driven disparities are evident, the information must be disseminated in a sensitive and 
non-threatening manner. In order to maintain anonymity, information on clinicians 
will be presented as a group.  The prinicipal investigator and the individual who 
completed data entry completed a required on-line educational course regarding ethics 
in research.  Any information identifying the patient were kept locked in a drawer 
unless being used by the researcher or research assistant.  A list with the patient’s 
medical record and research number were also kept in a restricted access on line 
computer folder. 
Support From Site 
 The researcher was invited to a meeting of the health care system’s council of 
investigators to discuss and receive input regarding this study.  The administration of 
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the health care system allowed the principal investigator full access to the medical 
records of any patients seen at the clinic with a diagnosis of 250.xx and to insurance 
information, outcome data, and initiatives related to improved diabetes care within the 
health care system.  Two clinicians within the health care system agreed to serve as 
site mentor and were readily available to the principal investigator.   
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Chapter 4 
 
Data Analysis 
This study examined whether the percentage of clinicians following the 
protocol for controlling LDL levels differed among all included ethnic groups and 
between those with public or private insurance.  Assuming 50% of clinicians treating 
Caucasians follow the LDL treatment protocols, and 40% of clinicians treating the 
Black/African American population follow the protocol with 100 patients in each 
racial group, for a one-sided test with a level of significance alpha=0.05, there was 
36% power to detect a 10% (e.g. 50-40%) difference, 63% power to detect a 15% (e.g. 
55-40%) difference, and 86% power to detect a 20% (e.g.60-40%) difference.  Stata 
version 10 was the statistical software used to analyze the data.   
Description of the sample. 
Demographic characteristics. 
Over 50% of the sample of 75 patients were Caucasian, 25% were African 
American, and 20% were East African (Appendix E).  Just over a third (37%) of the 
sample was women with a large majority (63%) of African Americans being female.  
There were more African American females in the study (63.2%) than Caucasians or 
Eastern Africans. 
Caucasians were the most likely to be married (42%) and to have private insurance 
(73.2%).  Across all racial groups, patients were typically in their mid-50s.   
Private or public health insurance 
Insurance type of those individuals in the study closely matched insurance 
coverage of the patient population of all individuals who are patients at the clinic.  
Clinic-wide, 41% of patients have government insurance; 59% have private insurance 
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or are self pay (personal communication, finance director, September, 2010).   The 
percentage of patients in the study with government insurance was 38.7% (see 
Appendix F for demographic characteristics by payer)  As noted on Appendix E, a 
significantly larger percentage (73.2%) of Caucasian patients had private insurance 
than did African Americans (47.4%) and East Africans (46.7%).  
BMI/obesity. 
The average BMI in 2008 and 2009 was 33.7 and was nearly the same between 
Caucasions and African Americans (Appendix G). The BMI of  Eastern Africans 
(27.3) was significantly lower than African Americans (35) in both 2008 and 2009.  
As a group, Eastern Africans had the lowest BMIs but some of the highest LDLs.   
As noted on Appendix H, females were more likely to be morbidly obese than 
males.  Patients whose BMI was below 25 had the highest LDL (148) compared to 
those whose BMIs were over 25 or 30+.  This statistic may reflect lower BMIs of 
Eastern African patients although the sample size of Eastern Africans is quite small. 
Lifestyle changes. 
At any point in time, 50% of patients whose LDLs were out of control wanted 
to try lifestyle changes.  More Caucasians and African Americans than Eastern 
Africans wanted to try this approach to LDL management.  The small number (1) of 
Eastern Africans who preferred to try lifestyle changes (16.7%) brought down the 
sample size of all patients who wanted to try lifestyle changes (see Appendix I, actions 
taken during the year given baseline status on LDLs and medications).  
The primary focus of information presented on Appendix I is on those 
individuals whose LDLs were out of control.  It is important to understand these 
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groups can go in and out of control at any time during this study, i.e. the information 
in this study was not presented in a linear fashion. 
 Clinician driven disparities. 
As noted earlier, the sample size before exclusions included 417 patients, 235 
(56.4%) Caucasians and 182 (43.6%) Black/African Americans individuals who had a 
least three office visits within the 18 month time frame.  Of patients excluded because 
LDL was under control, 34.5% were Caucasian and 12.1% were Black/African 
American (see Appendix A). Therefore, more Caucasians were included in the initial 
sample (417) since they came in more frequently for health care and more were 
excluded because their LDLs were more often under control.  
The study sample (N=75) was not representative of the original query or the 
clinic population.  The study sample included more Black/African American patients 
than in the clinic population or the query (N=417).  The study sample of Caucasions 
was representative of the clinic population.  
This information suggests that at the start of the study the sample was a fairly 
homogenous group and was perhaps not representative of the entire patient population 
at the clinic, particularly Black/African Americans. The findings may have changed if 
the sample included Blacks/African Americans who did not come in to be seen and did 
not have lab work drawn in a timely manner.  
There was not a significant difference between Caucasians and Black/African 
Americans related to initiation of statins when LDL was out of control (Appendix I).  
The same number of individuals of all races had LDLs that were out of control and on 
a statin as those whose LDL was out of control and not on a statin.  This table shows 
appropriate management of patients who were on a statin and whose LDL was out of 
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control.  Medications were increased 46.4% of the time and changed 21.4% of the 
time.  Of note, medications were more frequently increased in African Americans who 
were on medications but whose LDLs were out of control.  If health care disparities 
were occurring at the clinic, one would expect medications would be increased less 
frequently in this group when compared to Caucasions.)  Conversely, half of all three 
groups who had LDLs above goal were not started on medications, regardless of race. 
LDL findings. 
Patients with suboptimally controlled LDLs at the beginning of the study’s 
time frame were more likely to be female (43%), privately insured (68%), and married 
(43%).  There were more Caucasians who had LDL under control at the beginning of 
the study; these individuals had slightly poorer control at the end of the study.  This 
finding is of interest since individuals with higher socioeconomic status often benefit 
from environment factors that would help control LDLs.  This may be related to the 
urban location of the clinic and, again, could not be generalized to other clinics.  
Patients whose LDL was out of control at the beginning of the study (Appendix J) 
were more likely to be female, privately insured, and married.  Patients whose LDL 
was under control at the end of the study’s time period were more likely to be older 
(60 vs. 54 years of age) and female (Appendix K); female patients were more 
successful at getting their LDLs under control given they were more likely to be out of 
control one year prior.  
Inclusion in this study required at least two LDLs and a minimum of three 
office visits between 1/1/2008 and 6/30/2009.  LDL values may have been obtained 
anywhere during this time frame; many individuals had more than two LDLs values 
and fourteen patients had more than the average 5 office visits (Appendix L).  Both of 
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these factors may be skewing the findings.  14 patients in the study came in for more 
than 5 office visits; one patient came in ten times. These factors may also be skewing 
data related to LDL measurement.   
Medication management related to LDL values was tracked during the study.  
The patients were divided into two groups, those who were and were not on 
medication when LDL was measured at baseline (see Appendix L) during the study.  
Of the 60.7% of patients whose LDL was out of control at first measurement, 78.6% 
were still out of control by the third office visit and 39.3% were still out of control by 
the fourth office visit.  At the beginning of the study, the largest group of patients had 
LDLs that were out of control and were not on medications (37.3%).  This may be 
related to the degree by which the LDL was out of control.  Table 2  illustrates LDL 
values all of which are considered out of control with the exception of  the first 
reading for patient 1. 
 
Table 2 
Examples of elevated LDL values over time 
Patient 1 70 115 127 121 126 115 
Patient 2 144 134 148 
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Only 40% of patients in the study whose LDL was suboptimally controlled at 
baseline and who were not on a statin at the beginning of the study were started on a 
statin.  However, of those patients who were on a medication but whose LDL was out 
of control at baseline, almost 50% had an increase in dose and 21% had a change in 
medication.  
According to current D5 measurements, LDLs should be under 100.  As 
illustrated above, some patients had LDL values that were close to but above 100.  
Clinicians often choose not to start or increase medications in patients when values are 
close to goal.  However, it is recommended patients with diabetes who also have 
certain comorbidities including hypertension and/or coronary atherosclerosis should 
maintain an LDL at or below 70.   
The majority of patients came in to the clinic three to five times during the time 
frame of the study and had two or more LDL values drawn during the approximately 
12 months when the person’s care was tracked.  At each of these data points, the 
patient was determined to have LDLs that are in or out of control and if the individual 
was taking a statin.  LDL value and use of medications could change over the time of 
data collection.  Therefore, an individual whose LDL was under control at time one 
may or may not have been under control by the end of the study.   
It is notable that at point one in data collection, 56/75 or 75% of individuals 
had LDL values above goal.  Of these 56 individuals, 50% of individuals were not on 
a medication and 50% were on medication. At the end of the study, 28% of patients 
had a LDL at goal, 70% were on statins; 49% of the patients who were not at goal 
were not on a statin. 
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Race/ethnicity. 
 There is discussion regarding the definition of race and ethnicity and use of 
these terms when discussing health care disparities.  It is often social rather than 
genetic factors that underlie the racial gap in society and in health care.  Hebert (2008) 
lists the differing definitions used by various organizations including the Agency for 
Healthcare Research and Quality (AHRQ), the IOM, and the World Health 
Organization (WHO).  This author adopts Hebert’s definition of race as a “social 
construct based on phenotype . . . .  [the observable, physical expression of genetic and 
environmentally determined characteristics] . . . . and as a marker for exposure to 
social factors that can influence health including socioeconomic position, lifestyle 
habits, and use of health care (p. 375).”  He defines ethnicity as another social 
construct that is based on a shared culture, ancestry, language, religion, and traditions.  
Given the overlap in these definitions, Hebert recommends the use of the blended 
term, race/ethnicity.    
 This study depended on race/ethnicity information supplied by the patient 
(usually over the telephone) when registering at the clinic for an initial appointment.  
This health care system currently provides reception staff with a brief script to assist in 
gathering race/ethnicity information or answering patient questions regarding the need 
for this information.  The fact that this health care system requests and records 
race/ethnicity is a more forward-thinking approach than some institutions which have 
not yet begun to collect information regarding race/ethnicity. Without collection of 
data regarding race/ethnicity, it might be assumed that there are no health care 
disparities.  Information regarding race/ethnicity is necessary to develop statistical 
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models that seek to measure disparities in care (Hasnain-Wynia, Pierce, Haque, 
Hedges Greising, Prince, & Sabin, 2007). 
CAM/patient preference. 
Only one person tried CAMs at any point throughout the entire study 
(Appendix I).  Ten of the 28 individuals with LDLs out of control at baseline and not 
on any medications had expressed a preference to try something other than statins; 5 
were Caucasian, 4 were African American, and 1 was Eastern African (Appendix M). 
Economic issues. 
Three patients whose LDLs were in control changed medications due to 
financial concerns or had changes in insurance that required a change in medication 
(Appendix J).  In all three cases, clinicians responded in an appropriate manner, e.g. 
referral to the clinic social worker, utilization of a low cost drug plan, or use of a 
medications on the patients pharmaceutical formulary.  It may be that most clinicians 
chose initial medications that are more economical for the patient so very few patients 
have concerns regarding the high cost of medications.  Cost was determined to be 
more of an issue for African American patients 37.5% of the time than for Caucasians 
or Eastern Africans.   
Side effects. 
 Side effects of statins may include myalgias, muscle weakness persisting for 
more than two days, nausea, abdominal pain, yellowing of skin and eyes.  Laboratory 
values used to assess medication side effects of statins include a creatinine kinase and 
alanine transaminase.  In this study, only six (8%) patients had side effects of the statin 
prescribed (Appendix N). 
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 Adherence issues. 
 Medication adherence issues were identified in 8 (10.7%) of all patients 
included in the study; this issue was most evident among Eastern Africans (60%).  
However, the sample number of Eastern Africans was quite small and included only 
nine individuals. 
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Chapter 5 
Discussion of Findings 
This study did not demonstrate the presence of clinician driven disparities but 
instead showed the need for improved care in the management of LDLs of all patients 
with diabetes regardless of race.   
Inclusion/exclusion criteria indicated more Black/African Americans were 
included due to poor control of LDLs, yet more of these individuals were excluded 
because of inadequate lab data.  Although the inclusion/exclusion criteria resulted in 
approximately the same percentage as Black/African Americans and Caucasians, the 
resulting study sample of 75 was a fairly homogenous group of patients who came in 
for lab testing and office visits on a regular basis.  Additional information regarding 
health care disparities might be obtained by taking a closer look at the individuals who 
were excluded as part of the study design.  In order to increase the sample size, 
especially the numbers of African Americans and Eastern Africans, it may be 
necessary to broaden the scope of the study to include other clinics within or outside 
this health care system. 
The researcher recommends several system changes related to the methodology 
of the study.  The study tool should be streamlined and validated.  This study tool 
extracted data at several different points in time during the time frame of the study.  
While some conclusions can be drawn from actions at each of these points in time, it 
would be most informative to use a tool that tracks the progression of clinician actions 
by analyzing the sequence of actions taken at each visit.   
44 
A large portion of time was spent during the chart review as the researcher 
searched the electronic medical record for information to allow the separation of 
African American and Eastern African patients.  The researcher recommends the use 
of a demographic tool with granular data reflecting the race/ethnicity of individuals 
who are currently residence of the community.  The tool should also contain an open 
“other” category for individuals whose race/ethnicity is not reflected in the drop down 
menu.  This “other” information could be used to adjust the demographic tool as 
demographics of the community change  Collection of this information has become 
more important with the increasing diversity of patients seen with in the health care 
system, each group with its unique psychosocial perspective and approach to lifestyle 
changes, particularly diet and exercise. 
It may be helpful to have experts in the management of LDL levels of patients 
with diabetes review the most current best practice recommendations in care of these 
patients.  The health care system where the study took place uses the Plan-Do-Check-
Act approach based on Deming’s Wheel (1986) which is helpful to identify and assist 
in management of gaps in the use of protocols and recommendations regarding models 
of care.   
It is important to have BMI measures that are accurate and obtained in a 
consistent manner.  In addition, as recommended in the writings of Dr. Edward 
Wagner, the assignment of diabetes registry management to one individual instead of 
individual clinician/nurse teams may facilitate increased numbers of patients seen at 
the clinic. 
Patient preference had a minimal effect on management of LDLs in this study.  
Most patients were willing to use medications for management of LDL and did not 
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object to increases in dose.  Very few patients experienced side effects of statins or 
voiced a preference regarding treatment including the wish for a trial of lifestyle 
changes or use of complimentary alternative medicine.  Only a small number of 
patients expressed concern regarding the cost of medications.  However, large 
numbers of patients had LDLs that were uncontrolled and should have been started on 
statins; others were taking a statin but the dose needed to be adjusted to bring LDL 
values to recommended levels. 
 This project was an extremely valuable learning experience.  The project 
confirmed the writer’s interest in research in the clinical setting and the opportunity to 
expand knowledge personally and to share and discuss the study findings with other 
individuals and health care systems. The writer has a clearer understanding of the 
research process including the importance of IRB approval and the ethical demands of 
research.  This study required the assistance and support of many individuals within 
and outside of the health care system including a research assistant, statistician, and 
physician informatics specialist.   
Conclusions/Recommendations Related to the Need for System Changes 
 This study showed a need for several system changes to improve care of all 
patients with diabetes who have elevated LDLs.  A work team should be employed to 
identify and manage gaps in clinician use of protocols.  The use of experts in evidence 
based practice regarding diabetes management and a change in focus of clinician 
education and continuing education toward improved management of chronic diseases 
would be helpful.   
The study results did not show clinician driven disparities.  However, results 
showed the need for system changes designed with a vision of equity in health care 
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that is aligned with the goal of improved patient outcomes for individuals of all races 
and ethnicities who have diabetes.  In addition, results may determine if the study tool 
is an appropriate tool for measurement of clinician actions in other areas of health care 
research. 
A system change is needed to improve adherence regarding minimal follow up 
visits and lab work.  A recommendation is to assign one care coordinator within the 
clinic the responsibility of using the diabetes registry to contact patients who have not 
been seen in a timely manner or who need lab work.  This fits well with the model of 
the health care home, a system change currenting used in several of this health care 
system’s primary care sites that has been shown to improve patient care, outcomes, 
and clinician satisfaction in care of patients with chronic illnesses.  Health care home 
assigns patients to one of four tiers and reimburses the health care system depending 
on complexity of care.  Level of complexity is determined using the number and type 
of diagnosed illnesses for each patient, the need for translation services for the patient 
and/or caregiver, and the presence of mental health issues.  Health care home 
reimbursement varies from tier 1 (least complex) of approximately $10 to tier 4 (most 
complex) of approximately $60 per patient per month.   
Accurate demographics and a complete patient problem list are key to 
receiving the highest possible reimbursement from third party payers (personal 
communications with director of health support and contractor for implementation of 
Epic in the clinical setting, October, 2010).  Even with the upcoming transition to 
Epic, clinicians will be required to enter patient diagnoses on the problem list.  The 
importance of population of the problem list will be stressed to clinicians during the 
roll out of Epic.  It is predicted Epic will allow improved data extraction from the 
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electronic medical records; this change should improved efficiency and accuracy for 
health care research with a combined goal of optimal patient outcomes and responsible 
stewardship of health care dollars. 
The data collection tool gathered information from the patient problem list 
regarding comorbidities and complications related to diabetes and LDL management.  
Hypertension is one of these comorbidities and complicates treatment of patients with 
diabetes.  Accurate information on the patient problem list is important since the 
recommended LDL goal of individuals with comorbidities is less than 70 mg/dL rather 
than a goal of 99 mg/dL or below in individuals with diabetes who do not have one of 
these comorbidites or complications. 
In this study, more specific information regarding Black/African American 
categories would have facilitated efficiency and accuracy in the determination of either 
African American or Eastern African race/ethnicity.  A system change working toward 
use of an improved race/ethnicity demographic tool with a drop down feature under 
each race of more granular data information of all patients is necessary.  Legal action 
at the national level mandating consistency in collection of more complete information 
among government agencies would have an impact would have an effect on data 
collection at the local level.  It may be helpful to conduct a public health campaign, 
similar to that of the Census Bureau, informing patients of the change in collection of 
race/ethnicity information as an effort to provide improved health care to all who live 
in the community.    
A systems change could focus on obtaining consistently accurate BMI 
information.  Many patients are measured with significantly different types of 
footwear and outer garments which vary from day to day and from season to season.  
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Although this study did not show health care disparities, this health care system may 
want to further explore issues related to discordance between health care providers and 
patients.  According to Chen, Fryer, Phillips, Wilson, and Joseph (2005), only 22% of African 
Americans perferred an African American clinician; 65% had no preference.  Caucasians 
preferred a Caucasian clinician 13% of the time; 75% had no preference.  Of those patients 
who had a preference, those whose preferences were met more often rated their care as 
excellent.  It is acknowledged patients may be guessing regarding the race/ethnicity of their 
clinician similar to guesses that may occur when the patient registers at this clinic.  At this 
time, the role of the patients’ beliefs and preferences as contributing factors related to health 
care disparities are unclear.  Although discordant patient-clinician race may not affect quality 
of care, having a concordant race provider might incentivize patients to follow up on care 
recommendations.  According to the authors, these findings are consistent with previous 
research and, based on the  findings, “the solutions for racial and ethnic disparities in health 
will need to go beyond increasing the number of minority physicians and attempting to teach 
cultural competence; rather, addressing discrimination in the health care system, increasing 
access to minority physicians, and improving the ways for patients to choose physicians may 
be more potent options for reducing racial disparities” (p. 142). 
Limitations of the Study 
The findings of this study are not generalizable to other clinics within this 
health care system or to other health care systems.  The diabetes assessment tool was 
developed by the researcher and has not been validated.   
Sample size was quite small which limited the ability to capture significant differences 
between Black/African Americans and Caucasians as well as affecting the reliability and 
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generalizability of the findings.  BMI measurements and patient problem lists are accepted 
with the understanding there are concerns regarding accuracy and completeness. 
The reseacher, a nurse practitioner familiar with LDL management in care of 
patients with diabetes and who has an understanding of the medical record, was solely 
responsible for the chart review and data collection.  Given a larger budget, additional 
clinicians could participate in the chart review allowing for comparison of findings. 
Dissemenation 
This information will be presented to the researcher’s advisor and professors at St. 
 Catherine University and key stakeholders at the health care system where the study took 
place.  Decisions regarding poster presentation and national meetings and publication will be 
made after completion of the study. 
Implications for nursing 
 This study supports the role of the doctorally prepared nurse as being aware of 
concerns in the practice setting and using leadership skills to incorporate evidence based 
practice guidelines and research to make system changes that improve patient care and 
outcomes in the clinic, community, and nation.  Working along with a Ph.D.  prepared 
statistician illustrated the benefits of combining efforts with a D.N.P. in research and a better 
understanding of specific patient care needs.   
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Appendix A 
Sample Size, Inclusion and Exclusion 
Criteria 
  
Cauca
-sian 
African 
Americ
an  
East 
Afric
an 
Blacks
: 
AA+E
A 
Tot
al 
Inclusion Criteria, n (% of initial 
sample)   
Had 3 office visits from Jan 08-June09 235 182 417 
56.4% 43.6%   
Exclusion Criteria, n (% of initial 
sample)   
LDLs under control throughout the study 81 22 103 
34.5% 12.1% 
24.7
% 
Inadequate information on LDLs 57 57 114 
24.3% 31.3% 
27.3
% 
Lab visits were in 2009, but after June 
30th 27 20 47 
Only had 1 LDL during study’s 
timeframe  9 14 23 
No LDL lab visits during study’s 
timeframe 20 22 42 
Never had an LDL  1 1 2 
Insurance Issues 28 8 36 
Unclear information re AA or EA NA 31 31 
DM care through endocrinology 17 5 21 
AA/BL but not AA or EA 15 15 
<3 office visits within during study’s 
timeframe 9 3 12 
Total Excluded, n (% of initial sample) 194 72 30 148 342 
     82.6% 81.3%   
Final Sample, n (% of final sample) 41 19 15 34 75 
     54.7%     45.3%   
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Appendix B 
Registration Options: Eastern African Countries and Languages  
Country Language Options 
Burundi French, Swahili 
Djibouti Arabic, Somali, French 
Eritrea Tigrinya, Arabic 
Ethiopia Amharic, Somali 
Kenya Swahili, Arabic, Somali 
Malawi Primary non-English language not offered 
Mozambique Swahili 
Rwanda French 
Somalia Somalia, Swahili, Arabic 
Tanzania Swahili 
Uganda Swahili 
Note. Does not included languages/dialects spoken but not included as option on clinic/system list. 
          From http://www.cdc.gov/2008. 
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Appendix C 
 
Insurances Accepted at Clinic 
 
Government 
 Medicaid 
  BCBS PMAP/MN Care 
  HP PMAP/MN Care 
  Medica PMAP/MNCare 
  Medicaid/MNCare/Champus 
  Ucare PMAP/MNCare 
 Medicare 
  BCBS MedicareBlue PPO 
  BCBS MCHO/SNP Secure Blue 
  BCBS Vantage Blue Cost 
  HP 65+ CAP 
  HP Freedom 65+ Cost 
  HP MSHO 
  Medica MSHO 
  Medica Seniors Cost 
  Medicare FFS 
  Medicare Private FFS 
  Ucare Seniors 
                           Private 
 Aetna  
 Americas PPO/TPA 
 BCBS   
 BCBS Mgd Care 
 HP Insured 
 HP Open Access Insured 
 HPOpen Access Self Insured 
 HP Out of Network 
 HP self Insured 
 Industrial 
 Medica Choice 
 Medica Elect 
 Medica SelectCare 
 No CF Grouping 
 Non Contracted 
 Other Commerical 
 Patient Choice 
 PrePay 
 Preferred One CHP 
 Preferred One PPO 
 Preferred One Specified 
 Self Pay 
 Special Processing 
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Appendix D 
 
                                                    DIABETES CHART AUDIT TOOL 
                                   Zip Code:  ______________ 
Res#    PROVIDER INITIALS       No. MD visits/time frame:                Contacts w/HSN:    
    
                                                                No. known failed appts:                      Contacts w/IDC: 
           
Age   Gender   M Race/Eth   Cauc Payer   Gvmt   Private 
     F    AfAm    
       EastAf   
Marital Status     D   M    P    S    U    W    X           Interpreter /Language:                                  
Process Care Measures                 Comorbidities/Complications                        /        /         -  Ht:           Wt:             BMI: 
        /        /       -      /       /                401.   402.   403.   404.   405.   414.            /        /          -                   Wt:             BMI:       
                                 
STARTING WITH EARLIEST CHOL DURING ABOVE TIME FRAME 
 
Date of 1
st
 OV related to Process Care Measures :        / ____/______              
Date of Applicable Cholf:_______________ (Circle one:    LDL  <100;      LDL  ≥ 100) 
    Y  N   Side effects,  ____________ 
                     Y  N   Lifestyle coaching only 
                     Y  N   CAM 
                    Y  N   Start statining agent 
                                                   Y  N   Currently on statining agent 
       Y  N Statining agent discontinued by clinician 
                  Y  N   Increase statining agent     
                   Y  N   Change statining agent 
                                Y  N   Patient preference considered     
                                                                                  Y  N   Cost/insurance identified as an issue 
                                             Y  N   Appropriate action taken                                                                   
     Y  N   Advised repeat cholf or F/U  visit in :  ≤ 3 mos.  ≤ 1 yr.       
     Y  N   Measurement related to start/increase of medication 
     Y  N   Therapeutic delay in Rx mgmt.  (e.g.: Etoh)   
     Y  N    Adherence issue related to cholf mgmt identified 
 
 Date of Visit:_________________           Date of Related LDL:________________ 
          Y  N   LDL at goal? (most recent cholf-PREVIOUS/SAME DAY/p OV)      
    Y  N  Side effects,  ____________ 
                 Y  N   Lifestyle coaching only (no medications)  
                 Y  N   CAM                                                                                      
                             Y  N   Start lipid lowering agent 
                                                              Y  N   Currently on lipid lowering agent 
                  Y  N   Increase lipid lowering agent     
                   Y  N   Change lipid lowering agent 
                                Y  N   Patient preference considered     
                                                                                  Y  N   Cost/insurance identified as an issue 
                                             Y  N   Appropriate action taken                                                                   
     Y  N   Advised repeat cholf or F/U visit :  ≤ 3 mos.  ≤ 1 yr.      
     Y  N   Therapeutic delay in Rx mgmt.  (eg: Etoh) 
     Y  N    Adherence issue related to cholf mgmt identified 
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 Date of Visit:_________________          Date of Related LDL:________________  
           Y  N   LDL at goal? (most recent cholf- PREVIOUS/SAME DAY/p OV)     NA   ___________  
         Y  N  Side effects,  ____________ 
                 Y  N   Lifestyle coaching only (no medications)  
                 Y  N   CAM                                                                                      
                                Y  N   Start lipid lowering agent 
                                                              Y  N   Currently on lipid lowering agent 
       Y  N   Lipid lowering agent discontinued by clinician 
        Y  N   Increase lipid lowering agent     
                                                                    Y  N   Change lipid lowering agent 
                                 Y  N   Patient preference considered     
                                                                                   Y  N   Cost/insurance  identified as an issue 
                                                Y  N  Appropriate action taken 
    Y  N   Advise repeat cholf or F/U visit in :  ≤ 3 mos.  ≤ 1 yr.     
    Y  N   Therapeutic delay in Rx mgmt.  (e.g.:  Etoh) 
    Y  N    Adherence issue related to cholf mgmt identified 
     
 Date of Visit:_________________        Date of Related LDL:________________  
          Y  N   LDL at goal? (most recent cholf PREVIOUS/SAME DAY/p OV )     NA   ___________ 
       Y  N    Elevated LFTs, CPK, myalgia, ____________ 
                 Y  N   Lifestyle coaching only (no medications)  
                 Y  N   CAM                                                                                      
                                Y  N   Start lipid lowering agent 
                                                              Y  N   Currently on lipid lowering agent 
       Y  N   Lipid lowering agent discontinued by clinician 
                  Y  N   Increase lipid lowering agent     
                   Y  N   Change lipid lowering agent 
                                Y  N   Patient preference considered     
                                                                                  Y  N   Cost/insurance identified as an issue 
                                            Y  N   Appropriate action taken 
     Y  N   Advised repeat cholf or F/U visit:  ≤ 3 mos.  ≤ 1 yr.     NA    ?  
     Y  N   Therapeutic delay in Rx mgmt.  (e.g.:  Etoh) 
     Y  N    Adherence issue related to cholf mgmt identified 
 
 Date of Visit:_________________                 Date of Related LDL:________________  
          Y  N   LDL at goal? (most recent cholf PREVIOUS/SAME DAY/p OV)   NA   ___________ 
    Y  N  Side effects,  ____________ 
                 Y  N   Lifestyle coaching only (no medications)  
                 Y  N   CAM                                                                                      
                                Y  N   Start lipid lowering agent 
                                                              Y  N   Currently on lipid lowering agent 
       Y  N   Lipid lowering agent discontinued by clinician 
                  Y  N   Increase lipid lowering agent     
                   Y  N   Change lipid lowering agent 
                                Y  N   Patient preference considered      
                                                                                  Y  N   Cost/insurance identified as an issue 
                                                                                 Y  N   Appropriate action taken 
      Y  N   Advised repeat cholf or F/U visit in :  ≤ 3 mos.  ≤ 1 yr.    
      Y  N   Therapeutic delay in Rx mgmt.  (e.g.: Etoh ) 
      Y  N    Adherence issue related to cholf mgmt identified 
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       Y  N Deceased 
 
 
ADDITIONAL INFORMATION/NOTES: 
 
 
 
  
 Initial/Date: Date: Date: Date: Date: 
Total chol        
Trigs                   
Ratio                    
HDL                 
LDL                     
      
A1C      
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Appendix E 
 Demographic Characteristics by Race  
  Race   
  Caucasian African American East African Total Sample 
Sample Size (%) 41 (54.7%) 19 (25.3%) 15 (20%) 75 
Average Age (SD) 56.7 (10.5) 55.1 (11.3) 53.7 (8.8) 55.7 (10.3) 
Female (%) 15 (36.6%) 12 (63.2%) * 1 (6.7%) 28 (37.3%) 
Privately Insured (%)  30 (73.2%) * 9 (47.4%) 7 (46.7%) 46 (61.3%) 
Married (%) 17 (41.5%) 6 (31.6%) 5 (33.3%) 28 (37.3%) 
Interpreter (%) (n=7)    
7/15 (46.7%) 7 (9.3%) 
• Language (%) 
(n=7) 
•  •  • Oromo 2/7 
• 7(9.3%) 
      Somali 5/7   
Notes:  SD = Standard Deviation 
* Significant at the 0.05 level 
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Appendix F 
Demographic Characteristics by Payer 
  
  
Payer 
Government Private 
Sample Size (%) 29 (38.7%) 46 (61.3%) 
Mean Age (SD) 57 (12.4) 55 (8.9) 
Female 12 (41.4%) 16 (34.8%) 
Married 5 (17.2%) 23 (50%) 
Interpreter 4 (13.8%) 3(6.5%) 
Language   Oromo 2/3 
  Somali 4/4 Somali 1/3 
Notes:  SD = Standard Deviation  
* Significant at the 0.05 level 
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Appendix G 
BMI and Obesity Measures by Race 
  Race 
Total   
Sample   
Caucasian 
African 
American 
East African 
Sample Size (%) 41 19 15 75 
Calendar Year 2008    
BMI - 2008       
     Sample Size 40 16 9 65 
     Average BMI 34.6 35.2 27.3 *   
     Standard 
Deviation 
5.77 5.51 3.72 
  
     Range 21.6, 48.0 27.0, 45.9 23.0, 33.0   
Obesity - 2008      
     BMI<25 1 0 3 4 
          Percent 2.5% 0.0% 33.3% 6.2% 
     BMI>=25 7 3 4 14 
          Percent 17.5% 18.8% 44.4% 21.5% 
     BMI>=30 32 13 2 47 
          Percent 80.0% 81.3% 22.2% * 72.3% 
Calendar Year 2009    
BMI - 2009      
     Sample Size 40 15 9 64 
     Average BMI 34.2 35.7 27.9 *   
     Standard 
Deviation 
6.0 5.94 3.22 
  
     Range 22.4, 48.0 26.3, 47.3 23.9, 32.9   
Obesity - 2009      
     BMI<25 3 0 3 6 
          Percent 7.5% 0.0% 33.3% 9.4% 
     BMI>=25 6 3 4 13 
          Percent 15.0% 20.0% 44.4% 20.3% 
     BMI>=30 31 12 2 45 
          Percent 77.5% 80.0% 22.2% * 70.3% 
Notes:  BMI = Body Mass Index 
* Differences between East Africans and Caucasians, and East Africans and African Americans were 
significant at the 0.05 level 
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Appendix H 
Demographic Characteristics by Obesity Measures, 2008 
  BMI Missing  Total   
  <25 25+ 30+ Data Sample 
Sample Size 4 14 47 10 75 
Race    
      
Age 53.3 55.4 56.6 53.1   
     Standard Deviation 7.4 9.3 10.7 11.8   
Female 1 3 22 2 28 
     Percent 25.0% 21.4% 46.8% * 20.0% 37.3% 
Private Insurance 2 9 32 3 46 
     Percent 50.0% 64.3% 68.1% 30.0% 61.3% 
Married 2 5 17 4 28 
     Percent 50.0% 35.7% 36.2% 40.0% 37.3% 
Interpreter  1 3 1 2 7 
     Percent 25.0% 21.4% 2.1% * 20.0% 9.3% 
Language     
      
Oromo 2/7 1 1   0 7 
Somali 5/7   2 1 2   
Last LDL Values 148.0 ** 115.6 113.8 118.0 116.5 
     Median 137 116 111 113 114 
     Standard Deviation 42.0 23.8 29.4 25.5 29.1 
% Last LDL at Goal  0 3 16 2 21 
     Percent 0.0% 21.4% 34.0% 20.0% 28.0% 
Notes:  BMI = Body Mass Index 
* Differences between BMI groups 30+ and 25+, and BMI groups 30+ and <25 were significant at the 
0.05 level 
** Differences between BMI groups <25 and 25+, and BMI groups <25 and 30+ were significant at the 
0.05 level 
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Appendix I 
Actions Taken During the Year Given Baseline Status on LDLs and Medications 
Baseline LDL<100 LDL>=100 Total 
Sample Size 19 56 75 
  On Meds No Meds On Meds No Meds   
Group 1 2 3 4 Total 
Sample Size 15 4 28 28 75 
Lifestyle 0 2 (50%) 0  14 (50%) 16 (21.3%) 
Nutritional/CAM 0 0 0 1 (3.6%) 1 (1.3%) 
Start Medications 5 (33.3%) 0 2 (7.1%) 
11 
(39.3%) 18 (24%) 
Discontinued Meds 2 (13.3%) 0 1 (3.6%) 0 3 (4.0%) 
Increased Dose of Meds 3 (20%) 0 
13 
(46.4%) 4 (14.3%) 20 (26.7%) 
Changed Meds 3 (20%) 0 6 (21.4%) 1 (3.6%) 10 (13.3%) 
Caucasian On Meds No Meds On Meds No Meds   
Sample Size 10 3 14 14 41 
Lifestyle 0 1 (33.3%) 0 8 (57.1%) 9 (22%) 
Start Medications 2 (20%) 0 0 4 (28.6%) 6 (14.6%) 
Discontinued Meds 1 (10%) 0 1 (7.1%) 0 2 (4.9%) 
Increased Meds 3 (30%) 0 6 (42.9%) 2 (14.3%) 11 (26.8%) 
Changed Meds 1 (10%) 0 2 (14.3%) 0 3 (7.3%) 
African American On Meds No Meds On Meds No Meds   
Sample Size 2 1 8 8 19 
Lifestyle 0 1 (100%) 0 5 (62.5%) 6 (31.6%) 
Nutritional/CAM 0 0 0 1 (12.5%) 1 (5.3) 
Start Medications 0 0 0 3 (37.5%) 3 (15.8%) 
Discontinued Meds 1 (50%) 0 0 0 1 (5.3%) 
Increased Meds 0 0 5 (62.5%) 1 (12.5%) 6 (31.6%) 
Changed Meds 1 (50%) 0 4 (50%) 0 5 (26.3%) 
East African           
Sample Size 3 0 6 6 15 
Lifestyle 0 0 1 (16.7%) 1 (6.7%) 
Start Medications 3 (100%) 2 (33.3%) 4 (66.7%) 9 (60%) 
Discontinued Meds 0 0 0 0 
Increased Meds 0 2 (33.3%) 1 (16.7%) 3 (20%) 
Changed Meds 1 (33.3%) 0 1 (16.7%) 2 (13.3%) 
All Blacks           
Sample Size 5 1 14 14 34 
Lifestyle 0 1 (100%) 0 6 (42.9%) 7 (20.6%) 
Start Medications 3 (60%) 0 2 (14.3%) 7 (50%) 12 (35.3%) 
Discontinued Meds 1 (20%) 0 0 0 1 (2.9%) 
Increased Meds 0 0 7 (50%) 2 (14.3%) 9 (26.5%) 
Changed Meds 2 (40%) 0 4 (28.6%) 1 (7.1%) 7 (20.6%) 
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Appendix J  
Demo Characteristics by LDL Under Control at Time One 
  
LDL Not in 
Control 
LDL in 
Control 
  LDL>=100 LDL<100 
Sample Size (%) 56 19 
Race (%)     
     Caucasian 28 (50%) 13 (68.4%) * 
     African American 16 (28.6%) 3 (15.8%) 
     East African 12 (21.4%) 3 (15.8%) 
Average Age (SD) 54.8 (10.2) 58.4 (10.7) 
Female (%) 24 (42.9%) * 4 (21.1%) * 
Privately Insured (%) 38 (67.9%) 8 (42.1%) * 
Married (%) 24 (42.9%) 4 (21.1%) * 
Interpreter (%) (n=7) 6 (10.7%) 1 (5.3%) 
Language (%) (n=7) Oromo 1/6 Oromo 1/1 
  Somali 5/6   
Notes:  SD = Standard Deviation 
* Differences significant at 0.05 level 
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Appendix K 
Demo Characteristics by LDL Under Control Within a Year 
  
LDL Not in 
Control 
LDL in 
Control 
  LDL>=100 LDL<100 
Sample Size (%) 54 21 
Race (%)     
     Caucasian 29 (53.7%) 12 (57.1%) 
     African American 12 (22.2%) 7 (33.3%) 
     East African 13 (24.1%) 2 (9.5%) 
Average Age (SD) 53.9 (10.6) 60.3 (8.3) * 
Female (%) 17 (31.5%) 11 (52.4%) * 
Privately Insured (%) 31 (57.4%) 15 (71.4%) 
Married (%) 21 (38.9%) 7 (33.3%) 
Interpreter (%) (n=7) 6 (11.1%) 1 (4.8%) 
Language (%) (n=7) Oromo 2/6   
  Somali 4/6 Somali 1/1 
Notes:  SD = Standard Deviation 
* Differences significant at 0.05 level 
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Appendix  L 
 Number Actions Taken Given Baseline Status on LDLs and Medications by Time Period  
  Baseline LDL<100 LDL>=100 
  Sample Size 19 56 
    On Meds   
No 
Meds   
On 
Meds   
No 
Meds   
  Group 1   2   3   4   
  Sample Size 15 4   28 28   
  
# Actions Taken 
In Each Time 
Period   
% No 
Actio
n   
% No 
Action   
% No 
Action   
% No 
Action 
T1 At Goal 15   4           
  0 actions 13 86.7% 4 100% 
   1 action 2 13.3%   
  2 actions         
  Not at Goal         28   28   
  0 actions     17 60.7% 13 46.4% 
  1 action     10 35.7% 15 53.6% 
  2 actions     1 3.6% 
T2 At Goal 11 73.3% 2 50.0% 4 14.3% 3 10.7% 
  0 actions 10 90.9% 2 100% 4 100% 2 66.7% 
   1 action 1 9.1%   1 33.3% 
  2 actions     
  Not at Goal 4 26.7% 2 50.0% 24 85.7% 25 89.3% 
  0 actions 2 50.0% 2 100% 20 83.3% 15 60.0% 
  1 action 2 50.0% 4 16.7% 10 40.0% 
  2 actions     
T3 At Goal 11 73.3% 1 25.0% 6 21.4% 4 14.3% 
  0 actions 8 72.7% 1 100% 6 100% 4 100% 
   1 action 3 27.3%   
  2 actions     
  Not at Goal 4 26.7% 3 75.0% 22 78.6% 24 85.7% 
  0 actions 3 75.0% 1 33.3% 17 77.3% 15 62.5% 
  1 action 1 25.0% 2 66.7% 5 22.7% 9 37.5% 
  2 actions     
T4 At Goal 6 40.0%     8 28.6% 3 10.7% 
  0 actions 6 100% 8 100% 3 100% 
   1 action     
  2 actions     
  Not at Goal 6 40.0% 1 25.0% 11 39.3% 11 39.3% 
  0 actions 4 66.7%     11 100% 6 54.5% 
  1 action 1 16.7% 1 100%   5 45.5% 
  2 actions 1 16.7%   
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did not have 4 
visits 3 3 9 14 
At Goal 5 33.3% 1 25.0% 3 10.7% 2 7.1% 
  0 actions 5 100% 1 100% 3 100% 2 100% 
   1 action   0.0%   0.0% 0.0% 
  2 actions   0.0%   0.0% 0.0% 
  Not at Goal 1 6.7%     6 21.4% 3 10.7% 
  0 actions 1 100%     5 83.3% 2 66.7% 
  1 action   0.0% 1 16.7% 1 33.3% 
  2 actions   0.0%   0.0% 0.0% 
  
did not have 5 
visits 9 3 19 23 
T6 At Goal 4 26.7%     4 14.3% 1 3.6% 
  0 actions 4 100% 4 100% 1 100% 
   1 action     0.0% 
  2 actions     0.0% 
  Not at Goal 2 13.3%     2 7.1% 1 3.6% 
  0 actions 2 100% 1 50.0% 0 0.0% 
  1 action   1 50.0% 1 100% 
  2 actions     
  
did not have 6 
visits 9 4 22 26 
T7 At Goal 4 26.7%     2 7.1% 1 3.6% 
  0 actions 4 100% 2 100% 1 100% 
   1 action     
  2 actions     
  Not at Goal         2 7.1%     
  0 actions   2 100% 
  1 action     
  2 actions     
  
did not have 7 
visits 11 4 24 27 
T8 At Goal 2 13.3%     2 7.1%     
  0 actions 2 100% 2 100% 
   1 action     
  2 actions     
  Not at Goal 2 13.3%     1 3.6% 1 3.6% 
  0 actions 1 50.0% 0 0.0% 0 0.0% 
  1 action 1 50.0% 1 100% 1 100% 
  2 actions     
  
did not have 8 
visits 11 4 25 27 
T9 At Goal 1 6.7%     1 3.6%     
  0 actions 1 100% 1 100%   
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   1 action         
  2 actions         
  Not at Goal 1 6.7%             
  0 actions 0 0.0%     
  1 action 1 100%       
  2 actions         
  < 9 visits 13 4   27 28   
T1
0 At Goal                 
  0 actions       
   1 action         
  2 actions         
  Not at Goal 1 6.7%             
  0 actions 1 100%     
  1 action         
  2 actions         
  < 10 visits 14   4   28   28   
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Appendix M 
Patient Issues During the Year Given Baseline Status on LDLs and Medications 
Baseline LDL<100 LDL>=100 Total 
Sample Size 19 56 75 
  On Meds No Meds On Meds No Meds   
Group 1 2 3 4 Total 
Sample Size 15 4 28 28 75 
Patient Preferences 1 (6.7%) 0 1 (3.6% 10 (35.7%) 12 (16%) 
Cost 1 (6.7%) 0 5 (17.9%) 1 (3.6%) 7 (9.3%) 
Appropriate Action 1 (6.7%) 0 5 (17.9%) 0 6 (8%) 
Caucasian           
Sample Size 10 3 14 14 41 
Patient Preferences 0 0 0 5 (35.7%) 5 (12.2%) 
Cost 1 (10%) 0 2 (14.3%) 1 (7.1%) 4 (9.8%) 
Appropriate Action 1 (10%) 0 2 (14.3%) 0 3 (7.3%) 
African American           
Sample Size 2 1 8 8 19 
Patient Preferences 0 0 0 4 (50%) 4 (21.1%) 
Cost 0 0 3 (37.5%) 0 3 (15.8%) 
Appropriate Action 0 0 3 (37.5%) 0 3 (15.8%) 
East African           
Sample Size 3 0 6 6 15 
Patient Preferences 1 (33.3%) 1 (16.7%) 1 (16.7%) 3 (20%) 
Cost 0 0 0 0 
Appropriate Action 0 0 0 0 
All Blacks           
Sample Size 5 1 14 14 34 
Patient Preferences 1 (20%) 0 1 (7.1%) 5 (35.7%) 7 (20.6%) 
Cost 0 0 3 (21.4%) 0 3 (8.3%) 
Appropriate Action 0 0 3 (21.4%) 0 3 (8.3%) 
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Appendix N 
Follow-up Issues During the Year Given Baseline Status on LDLs and Medications 
Baseline LDL<100 LDL>=100 Total 
Sample Size 19 56 75 
  On Meds No Meds On Meds No Meds   
Group 1 2 3 4 Total 
Sample Size 15 4 28 28 75 
Repeat Cholesterol Ck 12 (80%) 2 (50%) 24 (85.7%) 25 (89.3%) 63 (84%) 
Therapeutic Delay in Rx 1 (6.7%) 0 3 (10.7%) 4 (14.3%) 8 (10.7%) 
Adherence Issues 3 (20%) 0 10 (35.7%) 5 (17.9%) 18 (24%) 
Elevated Labs (re Group 2) 3 (20%) 0 3 (10.7%) 0 6 (8%) 
Caucasian           
Sample Size 10 3 14 14 41 
Repeat Cholesterol Ck 7 (70%) 1 (33.3%) 13 (92.9%) 11 (78.6%) 32 (78%) 
Therapeutic Delay in Rx 0 0 1 (7.1%) 2 (14.3%) 3 (7.3%) 
Adherence Issues 1 (10%) 0 2 (14.3%) 1 (7.1%) 4 (9.8%) 
Elevated Labs (re Group 2) 1 (10%) 0 0 0 1 (2.4%) 
African American           
Sample Size 2 1 8 8 19 
Repeat Cholesterol Ck 2 (100.0%) 1 (100.0%) 7 (87.5%) 8 (100.0%) 18 (94.7%) 
Therapeutic Delay in Rx 0 0 2 (25%) 1 (12.5%) 3 (15.8%) 
Adherence Issues 0 0 3 (37.5%) 2 (25%) 5 (26.3%) 
Elevated Labs (re Group 2) 1 (50%) 0 2 (25%) 0 3 (15.8%) 
East African           
Sample Size 3 0 6 6 15 
Repeat Cholesterol Ck 3 (100.0%) 4 (66.7%) 6 (100.0%) 13 (86.7%) 
Therapeutic Delay in Rx 1 (33.3%) 0 1 (16.7%) 2 (13.3%) 
Adherence Issues 2 (66.7%) 5 (83.3%) 2 (33.3%) 9 (60%) 
Elevated Labs (re Group 2) 1 (33.3%) 1 (16.7%) 0 2 (13.3%) 
All Blacks           
Sample Size 5 1 14 14 34 
Repeat Cholesterol Ck 5 (100.0%) 1 (100.0%) 11 (78.6%) 14 (100.0%) 31 (91.2%) 
Therapeutic Delay in Rx 1 (20%) 0 2 (14.3%) 2 (14.3%) 5 (14.7%) 
Adherence Issues 2 (40%) 0 8 (57.1%) 4 (28.6%) 14 (41.2%) 
Elevated Labs (re Group 2) 2 (40%) 0 3 (21.4%) 0 5 (14.7%) 
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